Conversely, large RCTs—such as those evaluating RAAS inhibition, β-blockers, and SGLT2 inhibitors—offer high-level evidence but typically target broad HF populations without molecular stratification (158). The gene discussed is SLC5A2; the disease is hydrops fetalis.